Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.


TSX:CPH - Post by User

Post by stockfyon Jan 24, 2021 3:43am
193 Views
Post# 32370058

Dirt-cheap CPH: EV-to-Rev is 0.8x, EV-to-EBITDA is 1.3x!

Dirt-cheap CPH: EV-to-Rev is 0.8x, EV-to-EBITDA is 1.3x!
All figures below are in USD.

CPH paid off its $1.7 million debt at October 30, 2020, according to its latest press release, facts below:
 
"As of September 30, 2020, the Company had cash of $4.7 million and $1.7 million drawn on the credit facility. The Company's credit facility has been paid off as at October 30, 2020."
 
So CPH generated free cash flow in October 2020 and also believes that it will continue to generate free cash flow during the remainder of Q4 2020 and 2021.

CPH would not use its cash of $4.7 million to pay off the debt of $1.7 million, if it was burning cash in Q4 2020 or if it expected to burn cash in 2021. Common sense.

So CPH is debt free with approximately $3 million in cash, as at October 30, 2020.
 
So Enterprise Value is about $16 million now at C$0.90.
 
Revenue and adjusted EBITDA in 2020 will be about $20 million and $11.5 million, respectively.
 
As a result, EV-to-2020 Revenue  and EV-to-2020 adj. EBITDA are about 0.8 times and 1.3 times, respectively, at C$0.90.

Dirt-cheap.


 
<< Previous
Bullboard Posts
Next >>